Flexion falls on FX006 trial hold

Flexion Therapeutics Inc. (NASDAQ:FLXN) fell $4.38 (23%) to $15.00 in early after-hours trading on Wednesday on post-market news that FDA placed a clinical hold on an ongoing Phase IIb trial of FX006 to treat osteoarthritis (OA) knee pain.

Flexion said the hold is due to an infection in one patient's knee joint after an injection of FX006. ...